Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization

Journal of Heart and Lung Transplantation

Volumn 18, Issue 2, 1999, Pages 160-165

  Stringham, James C ^a   Bull, David A ^a   Fuller, Thomas C ^a   Kfoury, Abdallah G ^a   Taylor, David O ^a   Renlund, Dale G ^a   Karwande, S V ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; FRESH FROZEN PLASMA; INOTROPIC AGENT; IRON; RECOMBINANT ERYTHROPOIETIN; VITAMIN K GROUP;

ADULT; ALLOIMMUNITY; ARTICLE; ASSISTED CIRCULATION; BLOOD COMPONENT THERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; HEMATOCRIT; HLA SYSTEM; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIZATION; SEROLOGY; VENOUS OXYGEN TENSION;

ADULT; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEART-ASSIST DEVICES; HEMATOCRIT; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; PLASMA; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSPECTIVE STUDIES;

EID: 0032953671     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(98)00006-0     Document Type: Article

References (17)

1. Frazier O.H., Rose E.A., Macmanus Q., et al. Multicenter clinical evaluation of the Heartmate 1000 IP left ventricular assist device. Ann Thorac Surg. 53:1992;1080-1090.
2. Goldstein D.J., Seldomridge J.A., Chen J.M., et al. Use of Aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg. 59:1995;1063-1068.
3. Massad M.G., Cook D.J., Schmitt S.K., et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 64:1997;1120-1125.
4. Williams G.M., Hume D.M., Hudson R.P., et al. Hyperacute renal-homograft rejection in man. N Engl J Med. 279:1968;611-618.
5. Rose E.A., Pepino P., Barr M.L., et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 11:1992;S120-S123.
6. Smith J.D., Danskine A.J., Laylor R.M., et al. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol. 1:1993;60-65.
7. Delmonico F.L., Fuller A., Cosimi A.B., et al. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation. 36:1983;629.
8. McDonald J.C., Adamashvili I., Hayes J.M., et al. Soluble HLA class II concentrations in normal individuals and transplant recipients. Comparison with soluble HLA class I concentrations. Transplantation. 58:1994;1268.
9. Williams R.C., Malone C.C., Kao K.J. IgM rheumatoid factors react with human class I HLA molecules. J Immunol. 156:1998;1684-1694.
10. Spanier T.B., Oz M.C., Rose E.A., et al. Activation of NF-κB is central to the proinflammatory/procoagulant response in textured surface left ventricular assist device recipients and may be influenced by anti-inflammatory intervention with aspirin. J Heart Lung Transplant. 17:1998;80.
11. Rose E.A., Levin H.R., Oz M.C., et al. Artificial circulatory support with textured interior surfaces a counterintuitive approach to minimizing thromboembolism . Circulation. 90:1994;1187-1191.
12. Rafii S., Oz M.C., Seldomridge A., et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg. 60:1995;1627-1632.
13. Massad M.G., McCarthy P.M., Smedira N.G., et al. Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome? J Thorac Cardiovasc Surg. 112:1996;1275-1281.
14. McIntyre J.A., Higgins N., Britton R., et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Transplantation. 62:1996;691-693.
15. Glotz D., Haymann J.P., Sansonetti N., et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg) a potential tool for transplantation of immunized patients . Transplantation. 56:1993;335-337.
16. Scornik J.C., Salomon D.R., Fennell R.S., et al. Evaluation of immunosuppression as a treatment of pre-sensitization in renal transplant candidates. Clin Transplantation. 5:1991;121-125.
17. Robinson J.A., Radvany R.M., Mullen M.G., et al. Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation. Therapeutic Apheresis. 1:1997;147-151.